NeuroOne Medical Technologies Corp [NMTC] stock prices are up 9.45% to $0.59 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The NMTC shares have gain 8.52% over the last week, with a monthly amount drifted -39.59%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NeuroOne Medical Technologies Corp [NASDAQ: NMTC] stock has seen the most recent analyst activity on March 29, 2022, when Craig Hallum downgraded its rating to a Hold and also revised its price target to $2 from $6.
The stock price of NeuroOne Medical Technologies Corp [NMTC] has been fluctuating between $0.40 and $1.39 over the past year. NeuroOne Medical Technologies Corp [NASDAQ: NMTC] shares were valued at $0.59 at the most recent close of the market.
Analyzing the NMTC fundamentals
The NeuroOne Medical Technologies Corp [NASDAQ:NMTC] reported sales of 8.75M for trailing twelve months, representing a surge of 541.76%. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -1.18%, Pretax Profit Margin comes in at -1.25%, and Net Profit Margin reading is -1.25%. To continue investigating profitability, this company’s Return on Assets is posted at -1.11, Equity is -2.71 and Total Capital is -1.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5537 points at the first support level, and at 0.5214 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6066, and for the 2nd resistance point, it is at 0.6272.
Ratios To Look Out For
It’s worth pointing out that NeuroOne Medical Technologies Corp [NASDAQ:NMTC]’s Current Ratio is 3.58. On the other hand, the Quick Ratio is 2.35, and the Cash Ratio is 0.72. Considering the valuation of this stock, the price to sales ratio is 2.90, the price to book ratio is 6.16.
Transactions by insiders
Recent insider trading involved McClurg Ronald W., Chief Financial Officer, that happened on Apr 04 ’25 when 0.2 million shares were purchased. CEO and President, Rosa David A completed a deal on Apr 04 ’25 to buy 100000.0 shares. Meanwhile, Co-Founder, VP of Business Com Christianson Mark bought 30000.0 shares on Mar 14 ’25.
